NSRX — Nasus Pharma Ltd
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 2029039 ·
Last close
$2.55
Market Cap
$29.87M
52W High
$9.50
52W Low
$1.98
ADV30
15,896
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 12,449,000 | 7,818,000 | 1,453,000 |
| Dec 2025 | — | — | — | — | 5,004,000 | 1,237,000 | 2,236,000 |
| Jun 2025 | — | — | — | — | 639,000 | 203,000 | 4,953,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-24,462,000
Inventory
—
Receivables
—
ST Investments
$4,000,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -4,904,000 | -5,856,000 | 5,004,000 | 2,236,000 | 2,768,000 | -4,918,000 |
| Dec 2024 | 0 | -1,078,000 | -1,532,000 | 717,000 | 3,929,000 | -3,212,000 | -665,000 |
| Dec 2023 | 0 | -1,147,000 | -1,051,000 | 444,000 | 4,241,000 | -3,797,000 | -1,029,000 |
| Dec 2022 | 0 | -2,042,000 | -1,711,000 | 417,000 | 3,202,000 | -2,785,000 | -1,211,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NNVC | NANOVIRICIDES, INC. | $29.86M | $1.17 | — |
| BHST | BIOHARVEST SCIENCES INC. | $29.92M | $1.32 | — |
| ATHE | ALTERITY THERAPEUTICS LTD | $30.13M | $1.65 | — |
| RLFTY | MindMaze Therapeutics Holding SA | $30.24M | $0.18 | — |
| PRRUF | IMMUTEP Ltd | $29.47M | $0.02 | — |
News headlines (Yahoo Finance, 1h cache)
Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion
2026-11-17 13:00 · Yahoo
Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
2026-11-16 13:00 · Yahoo
Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026
2026-11-10 13:00 · Yahoo
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
2026-09-29 12:00 · Yahoo
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
2026-09-14 12:00 · Yahoo
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 11:30 · Yahoo
NSRX: First Half 2026 Financial Results
2026-08-21 11:00 · Yahoo
Nasus Pharma Announces Transition of Chief Financial Officer
2026-08-19 11:00 · Yahoo
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
2026-08-17 12:14 · Yahoo
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
2026-07-28 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.